Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers
Journal of Neuromuscular Diseases · 2025-09 · 12 (5) · 641-647
DOI: 10.1177/22143602251319177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 21.05.2025. Verfasst von Christopher F Spurney und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Center for Genetic Medicine Research, Children's National Heart Center, Children's National Hospital, Washington, DC, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Duchenne muscular dystrophy (DMD) is a progressive muscular disease associated with muscle fiber degeneration and increased inflammatory responses including Interleukin-1 beta (IL-1β) and other cytokines. Canakinumab (Ilaris) is an anti-human IL-1β monoclonal antibody that neutralizes IL-1β.
Methods
We completed an open-label, single dose pilot study of canakinumab 2 mg/kg subcutaneous injection in steroid naïve boys with DMD older than 2 years of age to determine safety and potential serum response biomarkers of efficacy at 4-weeks post treatment. Proteome profiling was performed using high throughput multiplexing aptamer SomaScan assay based technology targeting 1,500 unique serum proteins.
Results
Three subjects completed the study with no adverse events reported and no significant changes in safety labs. Proteomic analysis within 4 weeks of treatment identified significantly decreased inflammation associated factors including plasma serine protease inhibitor, interleukin-6 receptor alpha, Lymphocyte antigen 86, Immunoglobulin D and myostatin. Significantly increased proteins included muscle-associated proteins aldolase A and lactate dehydrogenase B.
Conclusions
Canakinumab 2 mg/kg dose is safe for children with DMD and demonstrated potential response biomarkers of efficacy in treating related muscle disease. Canakinumab did not affect the circulating levels of IL-1β but did decrease some key proinflammatory markers and myostatin. Increased muscle specific proteins could be associated with increased physical activities or damage seen in young patients with DMD. Further studies using canakinumab for a longer treatment period may demonstrate increased benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Center for Genetic Medicine Research, Children's National Heart Center, Children's National Hospital, Washington, DC, USA.
- Division of Neurology, Children's National Hospital, Washington, DC, USA.
- Division of Biostatistics, Children's National Hospital, Washington, DC, USA.
- School of Pharmacy and Pharmaceutical Sciences, Binghamton University-SUNY, Binghamton, NY, USA.
ORCID-Profile: Jessica Chong, Heather Gordish-Dressman, Yetrib Hathout
Zitieren
APA
Spurney, C. F., Chong, J., Gordish-Dressman, H., & Hathout, Y. (2025). Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers. Journal of Neuromuscular Diseases, 12(5), 641-647. https://doi.org/10.1177/22143602251319177
Vancouver
Spurney CF, Chong J, Gordish-Dressman H, Hathout Y. Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers. Journal of Neuromuscular Diseases. 2025;12(5):641-647. doi:10.1177/22143602251319177
BibTeX
@article{Spurney2025,
author = {Spurney, Christopher F and Chong, Jessica and Gordish-Dressman, Heather and Hathout, Yetrib},
title = {Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers},
journal = {Journal of Neuromuscular Diseases},
year = {2025},
volume = {12},
number = {5},
pages = {641--647},
doi = {10.1177/22143602251319177}
}
EUVIMED